Metrics to compare | COEGIN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOEGINPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | 1.0x | −0.2x | |
PEG Ratio | −0.38 | 0.95 | 0.00 | |
Price/Book | 10.9x | 3.5x | 2.6x | |
Price / LTM Sales | 151.9x | 22.6x | 2.7x | |
Upside (Analyst Target) | - | 0.0% | 66.0% | |
Fair Value Upside | Unlock | 28.8% | 10.8% | Unlock |
Coegin Pharma AB (publ), a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals. The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma. Coegin Pharma AB (publ) was founded in 2005 and is headquartered in Lund, Sweden.